Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $104.80.

A number of research analysts have weighed in on IRON shares. BMO Capital Markets cut their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Cantor Fitzgerald lowered their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, January 21st. Finally, Morgan Stanley set a $75.00 target price on shares of Disc Medicine in a research note on Tuesday, February 17th.

Disc Medicine Stock Performance

NASDAQ IRON opened at $60.09 on Monday. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The firm has a market cap of $2.29 billion, a P/E ratio of -10.03 and a beta of 0.87. The stock’s 50-day moving average is $67.77 and its 200-day moving average is $75.81.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. Sell-side analysts anticipate that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Insider Transactions at Disc Medicine

In other news, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $833,775.04. Following the sale, the chief executive officer directly owned 226,064 shares in the company, valued at $14,210,383.04. The trade was a 5.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider William Jacob Savage sold 7,378 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $65.88, for a total value of $486,062.64. Following the transaction, the insider directly owned 85,211 shares of the company’s stock, valued at $5,613,700.68. This represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 54,522 shares of company stock worth $3,579,979. 3.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Disc Medicine

Large investors have recently bought and sold shares of the company. RA Capital Management L.P. grew its stake in shares of Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after purchasing an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock worth $120,566,000 after purchasing an additional 108,197 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.